Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 62 Carcinoma, Hepatocellular 25 Neoplasm Metastasis 15 Rectal Neoplasms 11 Colonic Neoplasms 10 Gastrointestinal Stromal Tumors 9 Sarcoma 6 Ovarian Neoplasms 5 Osteosarcoma 5 Glioblastoma 5 Cholangiocarcinoma 5 Stomach Neoplasms 4 Melanoma 4 Liver Neoplasms 4 Sarcoma, Ewing 3 Pancreatic Neoplasms 3 Neoplasms 3 Leukemia, Myeloid, Acute 3 Esophageal Neoplasms 3 Colorectal Cancer Metastatic 3 Carcinoma, Non-Small-Cell Lung 3 Thyroid Neoplasms 2 Rhabdomyosarcoma 2 Myelodysplastic Syndromes 2 Multiple Myeloma 2 Mesothelioma, Malignant 2 Lymphoma, Non-Hodgkin 2 Hematologic Neoplasms 2 Hemangiosarcoma 2 Gastrointestinal Neoplasms 2

Interventions

tislelizumab 1 regorafenib 1 Trace amine-associated receptor 1 1 Thymalfasin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × MCRC × regorafenib × Clear all

NCT06829355 2025-02-17

THYMI

Beijing Friendship Hospital

Phase 2 Recruiting

MCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡